Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants

• Published in: Science (American Association for the Advancement of Science) Vol. 374; no. 6575; pp. 1621 - 1626
• Main Authors: McCallum, Matthew, Walls, Alexandra C., Sprouse, Kaitlin R., Bowen, John E., Rosen, Laura E., Dang, Ha V., De Marco, Anna, Franko, Nicholas, Tilles, Sasha W., Logue, Jennifer, Miranda, Marcos C., Ahlrichs, Margaret, Carter, Lauren, Snell, Gyorgy, Pizzuto, Matteo Samuele, Chu, Helen Y., Van Voorhis, Wesley C., Corti, Davide, Veesler, David
• Format: Journal Article
• Language: English
• Published: United States The American Association for the Advancement of Science 24.12.2021
• Subjects: 2019-nCoV Vaccine mRNA-1273 - immunology; ACE2; Ad26COVS1 - immunology; Affinity; Angiotensin; Angiotensin-converting enzyme 2; Angiotensin-Converting Enzyme 2 - metabolism; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - immunology; Antibodies, Neutralizing - metabolism; Antibodies, Viral - blood; Antibodies, Viral - immunology; Antibodies, Viral - metabolism; Antigens; Antigens, Viral - chemistry; Antigens, Viral - immunology; Binding; BNT162 Vaccine - immunology; Coronaviruses; COVID-19; COVID-19 Vaccines - immunology; Cryoelectron Microscopy; Disease transmission; Glycoproteins; Humans; Immune Evasion; Immunotherapy; Models, Molecular; Monoclonal antibodies; Mutation; Neutralizing; Peptidyl-dipeptidase A; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Receptors; Receptors, Coronavirus - metabolism; Recognition; Respiratory diseases; SARS-CoV-2 - chemistry; SARS-CoV-2 - genetics; SARS-CoV-2 - immunology; SARS-CoV-2 - pathogenicity; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - chemistry; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - immunology; Spike Glycoprotein, Coronavirus - metabolism; Vaccines; Viral diseases

In the course of the COVID-19 epidemic, variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge, some of which evade immunity or increase transmission. In late 2020, the Delta and Kappa variants were detected, and the Delta variant became globally dominant by June...